This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy
- Myeloid neoplasms after chemotherapy and PRRT: myth and reality
- Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
- Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments
- Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer
- Synthesis and Biologic Evaluation of 64Cu-Labeled Rhenium-Cyclized {alpha}-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
- Gelatin-Based Plasma Expander Effectively Reduces Renal Uptake of 111In-Octreotide in Mice and Rats
- Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide
- Preparation and Biological Evaluation of Copper-64-Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator
- High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes
- Radioiodination via D-Amino Acid Peptide Enhances Cellular Retention and Tumor Xenograft Targeting of an Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody